Lexeo Therapeutics (LXEO) Fundamental Analysis: Revenue, Earnings & Valuation

3.84 / 10

Netural

Fundamental analysis rates LXEO as neutral with a 3.8/10 quality score. Positive factors include cash‑to‑market value and inventory turnover, while asset‑to‑market, revenue‑to‑market and PB‑ROE are weak. Overall fund score 3.84 indicates limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight12.18%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.15%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight16.16%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.15%

1M Return-0.63%

PB-ROE

Value0.47

Score1/3

Weight13.54%

1M Return5.29%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight-0.93%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.08%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight9.35%

1M Return4.32%

Asset-MV

Value-0.49

Score2/3

Weight31.25%

1M Return12.22%

Cash-MV

Value-0.09

Score2/3

Weight14.36%

1M Return5.94%

Is LXEO undervalued or overvalued?

LXEO scores 3.84/10 on fundamentals and holds a Fair valuation at present. Backed by its -55.00% ROE, 0.00% net margin, -4.20 P/E ratio, 1.70 P/B ratio, and 39.81% earnings growth, these metrics solidify its Netural investment rating.